Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: AbbVie | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: AbbVie

HUMIRA sales down 18% in the quarter due to biosimilar competition

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

AbbVie
4Q Revenues: $8.3 billion (+7%)
4Q Loss: $1.8 billion (earnings were $52,000 4Q17)
FY Revenues: $32.8 billion (+16%)
FY Earnings: $5.7 billion (+7%)
Comments: Global HUMIRA sales were $19.9 billion, up 8% for the year. In the U.S., HUMIRA sales grew 9% percent in the quarter. Internationally, HUMIRA sales declined 18% due to biosimilar competition.
Global revenues from the hematologic oncology portfolio were $1.1 billion for the year, up 50%, with global IMBRUVICA sales of $1.0 billion, an increase of 42%, and global VENCLEXTA revenues were $124 million. Fourth-quarter global HCV net revenues were $862 million.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters